- Home
- AMWD vs VOR Comparison
AMWD vs VOR Comparison
Compare AMWD & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMWD | VOR |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.8M | 755.7M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMWD | VOR |
|---|---|---|
| Price | $42.05 | $15.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $63.50 | $45.44 |
| AVG Volume (30 Days) | 203.7K | ★ 1.2M |
| Earning Date | 05-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,709,585,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.51 | $0.13 |
| 52 Week High | $72.16 | $49.95 |
Technical Indicators
Market Signals| Indicator | AMWD | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 55.16 |
| Support Level | $37.44 | $11.38 |
| Resistance Level | $42.58 | $16.88 |
| Average True Range (ATR) | 1.70 | 1.63 |
| MACD | 0.91 | 0.05 |
| Stochastic Oscillator | 77.06 | 50.81 |
Price Performance
Historical ComparisonAbout AMWD American Woodmark Corporation
American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.